The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...

Star Hospitals in Hyderabad has launched a dedicated Heart Failure Clinic to address the rising cardiac health crisis. The ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Scientists have discovered that four health habits — which include sleep quality and nicotine use — were the most important ...

For patients with atrial fibrillation, catheter ablation reduces the risks for ischemic stroke at more than 30 days, mortality, and HF hospitalization.

Bayer AG BAYRY announced that the FDA has approved a label expansion of kidney disease drug Kerendia (finerenone). The ...

For each 1-μg/m3 increase in the past 2-year average smoke PM2.5, the risk for heart failure was increased by 1.014% compared with nonsmoke PM2.5; annually, this association corresponded to an ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...